A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia.
A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia.
复制标题
DOI：
10.1016/j.lrr.2017.01.003
复制
发表时间：
2017
影响因子：
--
通讯作者：
Chiu A
中科院分区：
文献类型：
--
作者：
Yao J;Douer D;Wang L;Arcila ME;Nafa K;Chiu A
Ph染色体是慢性粒细胞白血病（CML）的细胞遗传学标志。大多数CML患者携带e13 a2或e14 a2 BCR-ABL融合产物，而一小部分病例表达e1 a2或e19 a2转录本。我们报告一例慢性粒单核细胞白血病（CMML）患者，最初Ph染色体阴性，疾病迅速进展为急性髓系白血病（AML），并出现Ph染色体和BCR-ABL e6 a2，一种非常罕见的融合转录本。AML对治疗难治，随后出现Ph阴性白血病克隆并占主导地位。患者在疾病进展后不久死亡。
Philadelphia (Ph) chromosome is a cytogenetic hallmark of chronic myeloid leukemia (CML). Most patients with CML harbor either the e13a2 or e14a2 BCR-ABL fusion product, while a small subset of the cases expresses e1a2 or e19a2 transcripts. We report a patient with chronic myelomonocytic leukemia (CMML), initially Ph chromosome negative at presentation, with rapid disease progression to acute myeloid leukemia (AML) and appearance of Ph chromosome and BCR-ABL e6a2, a very uncommon fusion transcript. The AML was refractory to treatment with subsequent emergence and dominance of a Ph negative leukemic clone. The patient expired shortly after disease progression.